Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 1334Neoplasms 1111Carcinoma, Non-Small-Cell Lung 923Prostatic Neoplasms 755Colorectal Neoplasms 653Lung Neoplasms 626Neoplasm Metastasis 476Multiple Myeloma 449Leukemia, Myeloid, Acute 441Pancreatic Neoplasms 394Ovarian Neoplasms 390Melanoma 350Carcinoma, Hepatocellular 311Brain Neoplasms 293Recurrence 289Squamous Cell Carcinoma of Head and Neck 287Glioblastoma 263Head and Neck Neoplasms 256Stomach Neoplasms 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Carcinoma, Renal Cell 241Lymphoma 237Triple Negative Breast Neoplasms 234Endometrial Neoplasms 223Hematologic Neoplasms 220Uterine Cervical Neoplasms 217Urinary Bladder Neoplasms 213Glioma 208Lymphoma, Non-Hodgkin 206Sarcoma 204

Interventions

Gemcitabine 2Taxes 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × 90 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡